RE:RE:RE:RE:RE:Another New Job Posting: Paralegal, Corporate & Securities The only thing hilarious here is you, you moron.
From the FDA
Is eligibility for a priority review voucher affected by whether the sponsor intends to market the rare pediatric disease drug after approval?
The statute does not describe marketing of a rare pediatric disease drug as a prerequisite to receiving a priority review voucher. However, under section 529(e)(1), FDA may revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within 1 year following the date of approval.
Why else would they give 30% to Kedrion if they could just grab it and run? Talk about ridiculous!
Tax loss, give me a break, they could have cut their losses 2 years ago, why go through all this trouble? Oh wait, they want to keep collecting their fat salaries while running the company into the ground rather than moving on with their heads high, the execs want to to have failure on their rsums. More garbage!
And, yes MAD trial can take this long, do your research. You fool!
GunnerG wrote: This is a hilarious post.
They will not take it private, they are going to run it out of money very soon. Thomvest can use the tax losses against their winners and they get the IP because of the outstanding loans.
How long does it take to review the MAD results? Another dreamer. No product, no revenue and soon no listing.
You believe to receive the voucher it has to be commercialzed. Ridiculous statement, they got it the day the FDA approved the drug and it wasn't commercialized at that point.
Sell and run away. The time for hoping has passed.
aldo451 wrote: I hear you StockReddy, I am down big time...no denying. However, I will not sell at .95$
Everyone’s situation is different, I will hang on for a while longer…or go down with the ship.
I do not believe they will take this private, I could be wrong. And, contrary to what many are saying about letting the price drop and no news, what else can they possibly disclose? And, why would they hold a conference call? To reiterate that they are studying the MAD results once more?
My take is that after more in-depth analysis they figured that the return on Ryplazim was not worth the extra 10’s of millions (??) to bring it to market. This could also explain why Consonance jumped ship. They brought it across the finish line for the voucher and Kedrion was the only deal they had. I also believe that in order to receive the voucher the product has to be commercialized, hence Kedrion.
Finally, I think that it is just taking more time than anticipated to clean house and focus on the small molecules. My hope is that they post strong results with MAD and resume clinical trials for Fez….
Just my opinion of course and how I interpret this, some see the glass half-empty and others half-full.
Just don’t listen to all the noise on bullboards because it is just that a lot of unfounded craap…not facts.
StockReddy wrote: Aldo, I was not listening to anybody and lost al lot, hard to digest but true. I think playing casino is better then playing with LMNL. Everyone in my friends list made this year a lot of money in stocks and I only lost due to LMNL.